Company news

Celcuity Inc. news in 2026

Celcuity Inc.'s news releases, calls and decks from 2026, newest first.

View company

Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call

October 29, 2026

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

October 24, 2026

Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026

October 23, 2026

Celcuity Appoints David Gryska to Its Board of Directors

October 5, 2026

Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026

October 5, 2026

Celcuity Appoints David Gryska To Its Board Of Directors

October 2, 2026

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

September 30, 2026

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

August 26, 2026

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

August 13, 2026

Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call

August 6, 2026

Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

July 30, 2026

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

July 14, 2026

Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

June 3, 2026

Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032

June 3, 2026

Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- A...

June 1, 2026

Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026

June 1, 2026

Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

May 13, 2026

Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

May 7, 2026

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

May 1, 2026

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 24, 2026

Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call

March 17, 2026

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

March 8, 2026

Celcuity To Participate in Upcoming Investor Conferences

February 25, 2026

Celcuity Appoints Charles Romp to its Board of Directors

February 12, 2026

Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

February 4, 2026

Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

January 20, 2026

Calls in 2026

Decks in 2026